Understanding the opportunities and costs of pharmacogenetic-guided prescribing using routinely collected healthcare data

Using medical records from over 13 million individuals, we will quantify both the number of patients prescribed pharmacogenetic medicines and the total number of such prescriptions issued. Demographic and clinical factors—including age, gender, ethnicity, and health status—will be analysed to identify which patient groups would benefit most from prioritised pharmacogenetic testing.

We will also estimate the number of patients who could benefit from improved prescribing practices if pharmacogenetic testing were routinely available, as well as the potential cost savings for the NHS.

In addition, we will examine the potential harms associated with these medicines, including adverse drug reactions, drug allergies, side effects, intolerances, and instances where patients are required to change medications.